Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.

Georgina V Long,F Stephen Hodi,Evan J Lipson,Dirk Schadendorf,Paolo A Ascierto,Luis Matamala,Pamela Salman,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen J Gogas,Christopher D Lao,Juliana Janoski De Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Sarah Keidel, Anadil Shaikh,Anne Marie Sobiesk, Sonia Dolfi,Hussein A Tawbi

NEJM Evidence（2023）

引用 0|浏览5

暂无评分

摘要

Survival and Response with Nivolumab and RelatlimabIn this follow-up, patients with unresectable stage III or IV melanoma were randomly assigned to receive nivolumab + relatlimab or nivolumab alone. After approximately 6 months of additional follow-up, the combination's median progression-free survival was 10.2 months versus 4.6 months for monotherapy. The difference in overall survival rates was not statistically significant.

查看译文

关键词

advanced melanoma,nivolumab,relatlimab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要